Close Menu

NEW YORK– Myriad Genetics reported after the close of the market on Thursday that its fiscal second quarter revenues declined 10 percent year over year due to billing issues in its prenatal business.

For the three months ended Dec. 31, 2019 the firm reported total revenues of $195.1 million, compared to $216.8 million in the year-ago period and far short of the consensus Wall Street estimate of $209.8 million, and its previously stated guidance.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.